Anzai Medical

Executive Summary

Anzai Medical is a Japanese medical device company specializing in respiratory gating systems for radiation therapy. Founded in 2020, the company's core technology synchronizes radiation delivery with a patient's breathing cycle, improving tumor targeting accuracy while minimizing damage to healthy tissue. Operating in the oncology space, Anzai's commercial-stage product addresses a critical need in cancer treatment, particularly for thoracic and abdominal tumors affected by respiratory motion. With a small but focused team of 10-50 employees, the company is well-positioned to capture market share in the growing radiation therapy market, valued at over $7 billion globally. Its competitive advantage lies in precision and ease of integration with existing linear accelerators. While the company is privately held and lacks disclosed financials, its technology has the potential to become a standard of care, especially as hypofractionated and stereotactic body radiotherapy (SBRT) gain adoption. Key risks include competition from established players like Varian and Elekta, regulatory hurdles for international expansion, and the need for clinical evidence demonstrating superior outcomes.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for US market entry60% success
• Q4 2026Strategic partnership with a major linear accelerator manufacturer (e.g., Varian, Elekta)50% success
• Q2 2026Publication of pivotal clinical study results in a peer-reviewed journal80% success